Brokers Offer Predictions for ZVRA Q4 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities research analysts at Roth Capital issued their Q4 2025 earnings per share (EPS) estimates for Zevra Therapeutics in a note issued to investors on Tuesday, November 12th. Roth Capital analyst J. Aschoff forecasts that the company will post earnings per share of $0.04 for the quarter. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.63) per share.

A number of other research analysts have also issued reports on ZVRA. Canaccord Genuity Group reduced their price objective on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research report on Wednesday, September 18th. Roth Mkm upped their price target on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a research note on Monday, September 30th. Guggenheim initiated coverage on Zevra Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $20.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a research report on Friday, October 11th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $20.83.

Zevra Therapeutics Stock Down 2.4 %

NASDAQ:ZVRA opened at $8.45 on Thursday. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 1.80. The stock has a 50 day moving average of $7.97 and a 200-day moving average of $6.44. The firm has a market capitalization of $444.64 million, a PE ratio of -4.40 and a beta of 1.93. Zevra Therapeutics has a 52 week low of $4.18 and a 52 week high of $9.09.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 177.96% and a negative net margin of 342.63%. The business had revenue of $4.45 million for the quarter, compared to analyst estimates of $4.08 million. During the same quarter last year, the company earned ($0.15) EPS.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. International Assets Investment Management LLC grew its position in shares of Zevra Therapeutics by 594.0% in the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock valued at $48,000 after purchasing an additional 5,940 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in Zevra Therapeutics in the 1st quarter worth $64,000. The Manufacturers Life Insurance Company increased its holdings in shares of Zevra Therapeutics by 15.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after purchasing an additional 2,452 shares during the period. Hunter Associates Investment Management LLC acquired a new position in shares of Zevra Therapeutics during the third quarter valued at about $92,000. Finally, Intech Investment Management LLC acquired a new position in Zevra Therapeutics in the 3rd quarter valued at approximately $95,000. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.